News

Filter

Current filters:

NovartisFinancial

1 to 9 of 100 results

Novartis sees negative currency impact in 4th-qtr 2014; gives positive 2015 guidance

Novartis sees negative currency impact in 4th-qtr 2014; gives positive 2015 guidance

27-01-2015

Swiss pharma major Novartis, now the world’s largest drugmaker by sales, this morning posted financial…

FinancialNovartisPharmaceutical

Top 30 Pharmas spent $112 billion on R&D in 2013; report

Top 30 Pharmas spent $112 billion on R&D in 2013; report

17-12-2014

The world’s leading 30 pharmaceutical companies spent a combined $112 billion on research and development…

FinancialGlobalGlobalDataJohnson & JohnsonNovartisPfizerPharmaceuticalPharmaceutical sciencesResearch

Novartis venture fund leads $34 million financing for Annexon Bioscience

Novartis venture fund leads $34 million financing for Annexon Bioscience

17-12-2014

USA-based Annexon Bioscience says it has closed a $34 million Series A-1 to support the development of…

Annexon BioscienceANX005BiotechnologyFinancialNeurologicalNovartis

Increased scrutiny by EU5 health authorities will encourage off-label use of Avastin for wet-AMD

06-11-2014

Cost-constrained health authorities in the EU5 (France, Germany, Italy, Spain, and the UK) are increasingly…

AvastinBiosimilarsBiotechnologyEuropeFinancialLucentisMarkets & MarketingNovartisOphthalmicsRoche

This week’s third quarter pharma financial results in brief

This week’s third quarter pharma financial results in brief

31-10-2014

Several pharma, biotech and generics makers announced their third quarter results this week. Here are…

AmgenBayerDr Reddy's LaboratoriesFinancialGilead SciencesIpsenMerck & CoNicOxNovartisNovo NordiskPfizerRecordatiSanofiShireTeva

Novartis’ strong third-qtr boosted by sale of Idenix stake

Novartis’ strong third-qtr boosted by sale of Idenix stake

28-10-2014

Swiss pharma major Novartis this morning reported that sales for the third quarter of 2014 rose 4% to…

AlconFinancialNovartisPharmaceuticalSandozSwitzerland

CSL buys Novartis’ influenza vaccines business for $275 million

CSL buys Novartis’ influenza vaccines business for $275 million

27-10-2014

Swiss pharma major Novartis has agreed to divest its influenza vaccines business to Australia’s CSL…

Anti-viralsbioCSLCSL LimitedFinancialMergers & AcquisitionsNovartisPharmaceuticalVaccines

Novartis suspends commissioning of new Russian plant

13-10-2014

Swiss pharma major Novartis has decided to suspend the commissioning of its new Russian plant, which…

FinancialNovartisPharmaceuticalProductionRussia

1 to 9 of 100 results

Back to top